Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris

NCT01880320 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

503

Enrollment

INDUSTRY

Sponsor class

Conditions

Acne Vulgaris

Interventions

DRUG: CD0271 0.3% / CD1579 2.5%
DRUG: CD0271 0.1% / CD1579 2.5%
DRUG: Topical Gel Vehicle

Sponsor

Galderma R&D